SCHAUMBURG, Ill. — Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Norepinephrine Bitartrate Injection, USP in the United States as a therapeutic generic equivalent for Levophed, as approved by the U.S. Food and Drug Administration. Norepinephrine Bitartrate Injection, USP is indicated to raise blood pressure in adult patients with severe, acute hypotension. Norepinephrine Bitartrate Injection, USP is available as a carton of ten 4 mg per 4 mL (1 mg per mL) single-dose vials.
In line with Avenacy’s mission to champion patient safety and streamline patient care, Norepinephrine Bitartrate Injection, USP will feature the Company’s highly differentiated packaging and labeling to support accurate medication selection.
Avenacy will begin shipping Norepinephrine Bitartrate Injection, USP to wholesale partners this week. The Company is supported by a global network of development and contract manufacturing partners that have undergone successful FDA inspections based on cGMP standards.
Norepinephrine Bitartrate Injection, USP had U.S. sales of approximately $20 million for the twelve months ending in March 2026.
Please see link for Full Prescribing Information.
